SCH-486757

A detailed overview of the investigational drug SCH-486757

{{Drugbox | Verifiedfields = changed | verifiedrevid = 477002123 | IUPAC_name = (3R,4R)-1-[(2S)-2-[[3-(3,4-dichlorophenyl)-1,2,4-oxadiazol-5-yl]amino]-3,3-dimethylbutanoyl]-4-hydroxy-3-methoxy-4-phenylpiperidine | image = | width = | alt = | CAS_number = 123456-78-9 | PubChem = 12345678 | ChemSpiderID = 12345678 | UNII = | KEGG = | ChEMBL = | C=23 | H=28 | Cl=2 | N=4 | O=4 | molecular_weight = 479.40 g/mol }}

SCH-486757 is an investigational drug that was developed as a potential treatment for depression and anxiety disorders. It is classified as a serotonin-norepinephrine reuptake inhibitor (SNRI), which means it works by increasing the levels of the neurotransmitters serotonin and norepinephrine in the brain. These neurotransmitters are thought to play a key role in mood regulation.

Mechanism of Action

SCH-486757 functions by inhibiting the reuptake of serotonin and norepinephrine, thereby increasing their availability in the synaptic cleft. This action is similar to other SNRIs such as venlafaxine and duloxetine. By enhancing the levels of these neurotransmitters, SCH-486757 may help alleviate symptoms of depression and anxiety.

Pharmacokinetics

The pharmacokinetic profile of SCH-486757 includes its absorption, distribution, metabolism, and excretion. The drug is orally bioavailable and undergoes hepatic metabolism, primarily through the cytochrome P450 enzyme system. The half-life of SCH-486757 is approximately 12 hours, allowing for once or twice daily dosing.

Clinical Trials

SCH-486757 has undergone several phases of clinical trials to evaluate its efficacy and safety. In early phase trials, the drug demonstrated promising results in reducing symptoms of depression and anxiety. However, further studies are needed to confirm these findings and to assess the long-term safety of the drug.

Side Effects

Common side effects of SCH-486757 include nausea, dizziness, dry mouth, and insomnia. These side effects are similar to those observed with other SNRIs. Rare but serious side effects may include increased blood pressure and risk of serotonin syndrome.

Regulatory Status

As of the latest update, SCH-486757 is not approved for clinical use and remains an investigational compound. The development of the drug is subject to ongoing research and regulatory review.

Also see

• Serotonin-norepinephrine reuptake inhibitor
• Depression (mood disorder)
• Anxiety disorder
• Serotonin
• Norepinephrine